Menlo Therapeutics Inc. appointed Andrew Saik as Chief Financial Officer and Treasurer, effective March 23, 2020. Mr. Saik will report to David Domzalski, Chief Executive Officer, and will be responsible for leading the Company's global finance operations, including, financial planning and analysis, investor relations, accounting, tax, treasury, supply chain and information technology. He will be based at the Company's headquarters in Bridgewater, New Jersey.

Mr. Saik has over 20 years of accounting, finance, and general management experience at domestic and international companies. He was most recently CFO at PDS Biotechnology Inc. (formerly Edge Therapeutics). The Company also announced that Ilan Hadar, the Company's Chief Financial Officer and Treasurer since March 9, 2020 and the CFO and Israel Country Manager of Foamix Pharmaceuticals Ltd. (“Foamix”) from February 2014 until its merger with the Company on March 9, 2020 (the “Merger”), is leaving the Company.

Mr. Hadar resigned from his position as the Company's Chief Financial Officer effective March 22, 2020 (the “Resignation Date”).